Voncento
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Von Willebrand Disease
Conditions
Von Willebrand Disease
Trial Timeline
Oct 5, 2015 → Feb 15, 2018
NCT ID
NCT02552576About Voncento
Voncento is a approved stage product being developed by CSL for Von Willebrand Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02552576. Target conditions include Von Willebrand Disease.
What happened to similar drugs?
3 of 6 similar drugs in Von Willebrand Disease were approved
Approved (3) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02552576 | Approved | Completed |
Competing Products
14 competing products in Von Willebrand Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate | Roche | Pre-clinical | 33 |
| Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing Agents | Roche | Phase 3 | 47 |
| Neumega (Oprelvekin, Interleukin 11, IL-11) | Pfizer | Phase 2 | 27 |
| Oprelvekin, Interleukin 11, IL-11 | Pfizer | Phase 2 | 35 |
| recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11 | Pfizer | Phase 2 | 35 |
| efanesoctocog alfa (BIVV001) | Sanofi | Phase 1 | 29 |
| Biostate | CSL | Phase 3 | 40 |
| Voncento® | CSL | Pre-clinical | 26 |
| Blood coagulation Factor VIII and vWF, human | CSL | Approved | 43 |
| Biostate® + Biostate® | CSL | Phase 2/3 | 38 |
| VWF/FVIII products | CSL | Pre-clinical | 26 |
| Biostate | CSL | Phase 3 | 40 |
| Alphanate SD/HT | Grifols | Approved | 44 |
| plasma-derived FVIII/VWF concentrate | Grifols | Approved | 47 |